Artemether Completed Phase 3 Trials for Plasmodium Infections / Falciparum Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT01845701Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon
NCT02411994Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria
NCT00297882Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon
NCT01065116Artemether-Lumefantrine (AL) Unit Dose Pre-packs Versus Blister Packs
NCT01152931Antioxidant Micronutrients in Malaria
NCT00541385Pyronaridine Artesunate 3:1 Granule Formulation vs. CoartemĀ© Crushed Tablets in P. Falciparum Malaria Pediatric Patients
NCT00694694Azithromycin + Artesunate v Artemether-lumefantrine in Uncomplicated Malaria.
NCT00386763Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.
NCT00422084Pyronaridine Artesunate (3:1) Versus CoartemĀ® in P Falciparum Malaria Patients
NCT00123552Longitudinal Antimalarial Combinations in Uganda
NCT00118794Lapdap and Coartemether for Uncomplicated Malaria
NCT01916954Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Malaria in Pregnancy
NCT01939886Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)
NCT01374581Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria